Androgen receptor (degrader)
Assets acting on this target.
- Class
- AR PROTAC degrader
By indication
Related mechanisms
Androgen receptor (degrader) drugs compared
3 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| HRS-5041 | Jiangsu Hengrui Pharmaceuticals | PROTAC degrader | Phase 2 | Phase 2 in Prostate Cancer |
| Luxdegalutamide | Arvinas Inc., Novartis | protac | Phase 2 | Phase 2 in Metastatic Castration-Resistant Prostate Cancer |
| GSK5471713 | GlaxoSmithKline | undisclosed | Stage not recorded | Not recorded |